Cargando…

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability

During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lizhou, More, Kunal R., Ojha, Amrita, Jackson, Cody B., Quinlan, Brian D., Li, Hao, He, Wenhui, Farzan, Michael, Pardi, Norbert, Choe, Hyeryun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567765/ https://www.ncbi.nlm.nih.gov/pubmed/37821446 http://dx.doi.org/10.1038/s41541-023-00751-6

Ejemplares similares

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
por: Zhang, Lizhou, et al.
Publicado: (2020)

Functional importance of the D614G mutation in the SARS-CoV-2 spike protein
por: Jackson, Cody B., et al.
Publicado: (2021)

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
por: Ou, Tianling, et al.
Publicado: (2021)

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
por: Zhang, Lizhou, et al.
Publicado: (2020)

An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
por: Quinlan, Brian D., et al.
Publicado: (2020)

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
por: Guo, Yan, et al.
Publicado: (2021)

Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions
por: Zhang, Lizhou, et al.
Publicado: (2023)

Mechanisms of SARS-CoV-2 entry into cells
por: Jackson, Cody B., et al.
Publicado: (2021)

Insights from the Association of SARS-CoV S-Protein with its Receptor, ACE2
por: Li, Wenhui, et al.
Publicado: (2006)

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

The effects of PEGylation on LNP based mRNA delivery to the eye
por: Ryals, Renee C., et al.
Publicado: (2020)

AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery
por: Jackson, Cody B., et al.
Publicado: (2020)

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety
por: Vlatkovic, Irena
Publicado: (2021)

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
por: Kiaie, Seyed Hossein, et al.
Publicado: (2022)

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
por: Peng, Lei, et al.
Publicado: (2022)

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
por: Somiya, Masaharu, et al.
Publicado: (2021)

An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates
por: Ripoll, Manon, et al.
Publicado: (2022)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
por: Moyles, Iain R., et al.
Publicado: (2023)

Thermotropic effects of PEGylated lipids on the stability of HPPH-encapsulated lipid nanoparticles (LNP)
por: Kalyanram, Poornima, et al.
Publicado: (2021)

A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2
por: Wong, Swee Kee, et al.
Publicado: (2004)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
por: Hermosilla, Jesús, et al.
Publicado: (2023)

Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
por: Maugeri, Marco, et al.
Publicado: (2019)

Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
por: Tsiambas, Evangelos, et al.
Publicado: (2021)

Ionizable Lipids with Triazole Moiety from Click Reaction for LNP-Based mRNA Delivery
por: Wang, Yixiang, et al.
Publicado: (2023)

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
por: Zhang, Mengling, et al.
Publicado: (2020)

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
por: Granados-Riveron, Javier T., et al.
Publicado: (2021)

Single-cell suspension preparation from murine organs following in vivo mRNA-LNP exposure
por: Ndeupen, Sonia, et al.
Publicado: (2022)

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
por: Baldeon Vaca, Gabriela, et al.
Publicado: (2023)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
por: Patel, Nisarg, et al.
Publicado: (2023)

SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry
por: Huang, I-Chueh, et al.
Publicado: (2006)

The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy
por: Kuhn, Jens H., et al.
Publicado: (2006)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
por: Otsuka, Yuka, et al.
Publicado: (2018)

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
por: Kenjo, Eriya, et al.
Publicado: (2021)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
por: Liu, Cong, et al.
Publicado: (2022)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
por: Valentin, Antonio, et al.
Publicado: (2022)

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
por: Yu, Xiaojuan, et al.
Publicado: (2023)

ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
por: Daly, Owen, et al.
Publicado: (2023)

Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery
por: Das, Riddha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9air3917lvd9rvnhmj25sqeffr